Spinraza Continues to See Improvement in Sales Metrics in 2017
Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza has been witnessing improvement in infrastructure and payer access for spinal muscular atrophy (or SMA) patients in the US in 2017.